APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-Parkinson's Disease Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Anti-Parkinson's Disease Drugs Industry Growth and Trends Forecast to 2032

27 December 2025122 pages

Choose your research edition.

Industry ResearchAnti-Parkinson's Disease Drugs Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Parkinson's Disease Drugs Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Anti-Parkinson's Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Parkinson's Disease Drugs Market Outlook and Growth Opportunities 2026214 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Parkinson's Disease Drugs Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Anti-Parkinson's Disease Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Anti-Parkinson's Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Anti-Parkinson's Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-Parkinson's Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Anti-Parkinson's Disease Drugs include Zhejiang Huahai Pharmaceutical Co., Ltd., Tianjin Lisheng Pharmaceutical Co., Ltd., Ningbo Dahongying Pharmaceutical Co., Ltd., Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., Hunan Zhongnan Pharmaceutical Co., Ltd., Hangzhou Guoguang Pharmaceutical Co., Ltd., Guangzhou Kanghe Pharmaceutical Co., Ltd., Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. and Changzhou Kangpu Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Anti-Parkinson's Disease Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Anti-Parkinson's Disease Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Anti-Parkinson's Disease Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Anti-Parkinson's Disease Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Anti-Parkinson's Disease Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Anti-Parkinson's Disease Drugs Market by Company

Zhejiang Huahai Pharmaceutical Co., Ltd.

Tianjin Lisheng Pharmaceutical Co., Ltd.

Ningbo Dahongying Pharmaceutical Co., Ltd.

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Hunan Zhongnan Pharmaceutical Co., Ltd.

Hangzhou Guoguang Pharmaceutical Co., Ltd.

Guangzhou Kanghe Pharmaceutical Co., Ltd.

Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.

Changzhou Kangpu Pharmaceutical Co., Ltd.

Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.

Beijing Fuyuan Pharmaceutical Co., Ltd.

Valeant

Teva Pharmaceutical

Stada Arzneimittel

Roche Holding AG

Orion

Novartis

Merck

Lundbeck

Kyowa Kirin

GSK

Endo International plc

Desitin Arzneimittel

Boehringer Ingelheim

Bausch Health

Astellas Pharma

Apokyn

Akorn

Abbvie

Anti-Parkinson's Disease Drugs Segment by Type

Anticholinergics

Dopaminergics

Anti-Parkinson's Disease Drugs Segment by Application

Pharmacy

Hospital

Clinic

Other

Anti-Parkinson's Disease Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Parkinson's Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Parkinson's Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Parkinson's Disease Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Anti-Parkinson's Disease Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Anti-Parkinson's Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Anticholinergics Table 2. Major Company of Dopaminergics Table 3. Global Anti-Parkinson's Disease Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (K Units) Table 5. Global Anti-Parkinson's Disease Drugs Sales Market Share in Volume by Type (2021-2026) Table 6. Global Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (US$ Million) Table 7. Global Anti-Parkinson's Disease Drugs Sales Market Share in Value by Type (2021-2026) Table 8. Global Anti-Parkinson's Disease Drugs Price by Type (2021-2026) & (US$/Unit) Table 9. Global Anti-Parkinson's Disease Drugs Sales by Type (2027-2032) & (K Units) Table 10. Global Anti-Parkinson's Disease Drugs Sales Market Share in Volume by Type (2027-2032) Table 11. Global Anti-Parkinson's Disease Drugs Sales by Type (2027-2032) & (US$ Million) Table 12. Global Anti-Parkinson's Disease Drugs Sales Market Share in Value by Type (2027-2032) Table 13. Global Anti-Parkinson's Disease Drugs Price by Type (2027-2032) & (US$/Unit) Table 14. North America Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (K Units) Table 15. North America Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (K Units) Table 17. Europe Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (K Units) Table 21. Latin America Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Anti-Parkinson's Disease Drugs Industry Trends Table 25. Anti-Parkinson's Disease Drugs Industry Drivers Table 26. Anti-Parkinson's Disease Drugs Industry Opportunities and Challenges Table 27. Anti-Parkinson's Disease Drugs Industry Restraints Table 28. Global Anti-Parkinson's Disease Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Company (2021-2026) Table 30. Global Anti-Parkinson's Disease Drugs Sales by Company (2021-2026) & (K Units) Table 31. Global Anti-Parkinson's Disease Drugs Sales Share by Company (2021-2026) Table 32. Global Anti-Parkinson's Disease Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Anti-Parkinson's Disease Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Anti-Parkinson's Disease Drugs Major Company Production Sites and Headquarters Table 35. Global Anti-Parkinson's Disease Drugs Company, Product Type & Application Table 36. Global Anti-Parkinson's Disease Drugs Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Anti-Parkinson's Disease Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Anti-Parkinson's Disease Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Anti-Parkinson's Disease Drugs Sales by Region (2021-2026) & (K Units) Table 41. Global Anti-Parkinson's Disease Drugs Sales Market Share in Volume by Region (2021-2026) Table 42. Global Anti-Parkinson's Disease Drugs Sales by Region (2021-2026) & (US$ Million) Table 43. Global Anti-Parkinson's Disease Drugs Sales Market Share in Value by Region (2021-2026) Table 44. Global Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Anti-Parkinson's Disease Drugs Sales by Region (2027-2032) & (K Units) Table 46. Global Anti-Parkinson's Disease Drugs Sales Market Share in Volume by Region (2027-2032) Table 47. Global Anti-Parkinson's Disease Drugs Sales by Region (2027-2032) & (US$ Million) Table 48. Global Anti-Parkinson's Disease Drugs Sales Market Share in Value by Region (2027-2032) Table 49. Global Anti-Parkinson's Disease Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Anti-Parkinson's Disease Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (K Units) Table 52. Global Anti-Parkinson's Disease Drugs Sales Market Share in Volume by Application (2021-2026) Table 53. Global Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (US$ Million) Table 54. Global Anti-Parkinson's Disease Drugs Sales Market Share in Value by Application (2021-2026) Table 55. Global Anti-Parkinson's Disease Drugs Price by Application (2021-2026) & (US$/Unit) Table 56. Global Anti-Parkinson's Disease Drugs Sales by Application (2027-2032) & (K Units) Table 57. Global Anti-Parkinson's Disease Drugs Sales Market Share in Volume by Application (2027-2032) Table 58. Global Anti-Parkinson's Disease Drugs Sales by Application (2027-2032) & (US$ Million) Table 59. Global Anti-Parkinson's Disease Drugs Sales Market Share in Value by Application (2027-2032) Table 60. Global Anti-Parkinson's Disease Drugs Price by Application (2027-2032) & (US$/Unit) Table 61. North America Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (K Units) Table 62. North America Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (K Units) Table 64. Europe Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (K Units) Table 68. Latin America Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information Table 72. Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview Table 73. Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 75. Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Development Table 76. Tianjin Lisheng Pharmaceutical Co., Ltd. Company Information Table 77. Tianjin Lisheng Pharmaceutical Co., Ltd. Business Overview Table 78. Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 80. Tianjin Lisheng Pharmaceutical Co., Ltd. Recent Development Table 81. Ningbo Dahongying Pharmaceutical Co., Ltd. Company Information Table 82. Ningbo Dahongying Pharmaceutical Co., Ltd. Business Overview Table 83. Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 85. Ningbo Dahongying Pharmaceutical Co., Ltd. Recent Development Table 86. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Company Information Table 87. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Business Overview Table 88. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 90. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Development Table 91. Hunan Zhongnan Pharmaceutical Co., Ltd. Company Information Table 92. Hunan Zhongnan Pharmaceutical Co., Ltd. Business Overview Table 93. Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 95. Hunan Zhongnan Pharmaceutical Co., Ltd. Recent Development Table 96. Hangzhou Guoguang Pharmaceutical Co., Ltd. Company Information Table 97. Hangzhou Guoguang Pharmaceutical Co., Ltd. Business Overview Table 98. Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 100. Hangzhou Guoguang Pharmaceutical Co., Ltd. Recent Development Table 101. Guangzhou Kanghe Pharmaceutical Co., Ltd. Company Information Table 102. Guangzhou Kanghe Pharmaceutical Co., Ltd. Business Overview Table 103. Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 105. Guangzhou Kanghe Pharmaceutical Co., Ltd. Recent Development Table 106. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Company Information Table 107. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Business Overview Table 108. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 110. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Recent Development Table 111. Changzhou Kangpu Pharmaceutical Co., Ltd. Company Information Table 112. Changzhou Kangpu Pharmaceutical Co., Ltd. Business Overview Table 113. Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 115. Changzhou Kangpu Pharmaceutical Co., Ltd. Recent Development Table 116. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Company Information Table 117. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Business Overview Table 118. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 120. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Recent Development Table 121. Beijing Fuyuan Pharmaceutical Co., Ltd. Company Information Table 122. Beijing Fuyuan Pharmaceutical Co., Ltd. Business Overview Table 123. Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 125. Beijing Fuyuan Pharmaceutical Co., Ltd. Recent Development Table 126. Valeant Company Information Table 127. Valeant Business Overview Table 128. Valeant Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Valeant Anti-Parkinson's Disease Drugs Product Portfolio Table 130. Valeant Recent Development Table 131. Teva Pharmaceutical Company Information Table 132. Teva Pharmaceutical Business Overview Table 133. Teva Pharmaceutical Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Teva Pharmaceutical Anti-Parkinson's Disease Drugs Product Portfolio Table 135. Teva Pharmaceutical Recent Development Table 136. Stada Arzneimittel Company Information Table 137. Stada Arzneimittel Business Overview Table 138. Stada Arzneimittel Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Stada Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolio Table 140. Stada Arzneimittel Recent Development Table 141. Roche Holding AG Company Information Table 142. Roche Holding AG Business Overview Table 143. Roche Holding AG Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Roche Holding AG Anti-Parkinson's Disease Drugs Product Portfolio Table 145. Roche Holding AG Recent Development Table 146. Orion Company Information Table 147. Orion Business Overview Table 148. Orion Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Orion Anti-Parkinson's Disease Drugs Product Portfolio Table 150. Orion Recent Development Table 151. Novartis Company Information Table 152. Novartis Business Overview Table 153. Novartis Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Novartis Anti-Parkinson's Disease Drugs Product Portfolio Table 155. Novartis Recent Development Table 156. Merck Company Information Table 157. Merck Business Overview Table 158. Merck Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 159. Merck Anti-Parkinson's Disease Drugs Product Portfolio Table 160. Merck Recent Development Table 161. Lundbeck Company Information Table 162. Lundbeck Business Overview Table 163. Lundbeck Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 164. Lundbeck Anti-Parkinson's Disease Drugs Product Portfolio Table 165. Lundbeck Recent Development Table 166. Kyowa Kirin Company Information Table 167. Kyowa Kirin Business Overview Table 168. Kyowa Kirin Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 169. Kyowa Kirin Anti-Parkinson's Disease Drugs Product Portfolio Table 170. Kyowa Kirin Recent Development Table 171. GSK Company Information Table 172. GSK Business Overview Table 173. GSK Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 174. GSK Anti-Parkinson's Disease Drugs Product Portfolio Table 175. GSK Recent Development Table 176. Endo International plc Company Information Table 177. Endo International plc Business Overview Table 178. Endo International plc Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 179. Endo International plc Anti-Parkinson's Disease Drugs Product Portfolio Table 180. Endo International plc Recent Development Table 181. Desitin Arzneimittel Company Information Table 182. Desitin Arzneimittel Business Overview Table 183. Desitin Arzneimittel Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 184. Desitin Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolio Table 185. Desitin Arzneimittel Recent Development Table 186. Boehringer Ingelheim Company Information Table 187. Boehringer Ingelheim Business Overview Table 188. Boehringer Ingelheim Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 189. Boehringer Ingelheim Anti-Parkinson's Disease Drugs Product Portfolio Table 190. Boehringer Ingelheim Recent Development Table 191. Bausch Health Company Information Table 192. Bausch Health Business Overview Table 193. Bausch Health Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 194. Bausch Health Anti-Parkinson's Disease Drugs Product Portfolio Table 195. Bausch Health Recent Development Table 196. Astellas Pharma Company Information Table 197. Astellas Pharma Business Overview Table 198. Astellas Pharma Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 199. Astellas Pharma Anti-Parkinson's Disease Drugs Product Portfolio Table 200. Astellas Pharma Recent Development Table 201. Apokyn Company Information Table 202. Apokyn Business Overview Table 203. Apokyn Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 204. Apokyn Anti-Parkinson's Disease Drugs Product Portfolio Table 205. Apokyn Recent Development Table 206. Akorn Company Information Table 207. Akorn Business Overview Table 208. Akorn Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 209. Akorn Anti-Parkinson's Disease Drugs Product Portfolio Table 210. Akorn Recent Development Table 211. Abbvie Company Information Table 212. Abbvie Business Overview Table 213. Abbvie Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 214. Abbvie Anti-Parkinson's Disease Drugs Product Portfolio Table 215. Abbvie Recent Development Table 216. North America Anti-Parkinson's Disease Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 217. North America Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units) Table 218. North America Anti-Parkinson's Disease Drugs Sales Market Share by Country (2021-2026) Table 219. North America Anti-Parkinson's Disease Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 220. North America Anti-Parkinson's Disease Drugs Sales Market Share Forecast by Country (2027-2032) Table 221. North America Anti-Parkinson's Disease Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 222. North America Anti-Parkinson's Disease Drugs Market Size by Country (2021-2026) & (US$ Million) Table 223. North America Anti-Parkinson's Disease Drugs Market Share by Country (2021-2026) Table 224. North America Anti-Parkinson's Disease Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 225. North America Anti-Parkinson's Disease Drugs Market Share Forecast by Country (2027-2032) Table 226. Europe Anti-Parkinson's Disease Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 227. Europe Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units) Table 228. Europe Anti-Parkinson's Disease Drugs Sales Market Share by Country (2021-2026) Table 229. Europe Anti-Parkinson's Disease Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 230. Europe Anti-Parkinson's Disease Drugs Sales Market Share Forecast by Country (2027-2032) Table 231. Europe Anti-Parkinson's Disease Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 232. Europe Anti-Parkinson's Disease Drugs Market Size by Country (2021-2026) & (US$ Million) Table 233. Europe Anti-Parkinson's Disease Drugs Market Share by Country (2021-2026) Table 234. Europe Anti-Parkinson's Disease Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 235. Europe Anti-Parkinson's Disease Drugs Market Share Forecast by Country (2027-2032) Table 236. Asia-Pacific Anti-Parkinson's Disease Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 237. Asia-Pacific Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units) Table 238. Asia-Pacific Anti-Parkinson's Disease Drugs Sales Market Share by Country (2021-2026) Table 239. Asia-Pacific Anti-Parkinson's Disease Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 240. Asia-Pacific Anti-Parkinson's Disease Drugs Sales Market Share Forecast by Country (2027-2032) Table 241. Asia-Pacific Anti-Parkinson's Disease Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 242. Asia-Pacific Anti-Parkinson's Disease Drugs Market Size by Country (2021-2026) & (US$ Million) Table 243. Asia-Pacific Anti-Parkinson's Disease Drugs Market Share by Country (2021-2026) Table 244. Asia-Pacific Anti-Parkinson's Disease Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 245. Asia-Pacific Anti-Parkinson's Disease Drugs Market Share Forecast by Country (2027-2032) Table 246. Latin America Anti-Parkinson's Disease Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 247. Latin America Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units) Table 248. Latin America Anti-Parkinson's Disease Drugs Sales Market Share by Country (2021-2026) Table 249. Latin America Anti-Parkinson's Disease Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 250. Latin America Anti-Parkinson's Disease Drugs Sales Market Share Forecast by Country (2027-2032) Table 251. Latin America Anti-Parkinson's Disease Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 252. Latin America Anti-Parkinson's Disease Drugs Market Size by Country (2021-2026) & (US$ Million) Table 253. Latin America Anti-Parkinson's Disease Drugs Market Share by Country (2021-2026) Table 254. Latin America Anti-Parkinson's Disease Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 255. Latin America Anti-Parkinson's Disease Drugs Market Share Forecast by Country (2027-2032) Table 256. Middle East and Africa Anti-Parkinson's Disease Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 257. Middle East and Africa Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units) Table 258. Middle East and Africa Anti-Parkinson's Disease Drugs Sales Market Share by Country (2021-2026) Table 259. Middle East and Africa Anti-Parkinson's Disease Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 260. Middle East and Africa Anti-Parkinson's Disease Drugs Sales Market Share Forecast by Country (2027-2032) Table 261. Middle East and Africa Anti-Parkinson's Disease Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 262. Middle East and Africa Anti-Parkinson's Disease Drugs Market Size by Country (2021-2026) & (US$ Million) Table 263. Middle East and Africa Anti-Parkinson's Disease Drugs Market Share by Country (2021-2026) Table 264. Middle East and Africa Anti-Parkinson's Disease Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 265. Middle East and Africa Anti-Parkinson's Disease Drugs Market Share Forecast by Country (2027-2032) Table 266. Key Raw Materials Table 267. Raw Materials Key Suppliers Table 268. Anti-Parkinson's Disease Drugs Distributors List Table 269. Anti-Parkinson's Disease Drugs Customers List Table 270. Research Programs/Design for This Report Table 271. Authors List of This Report Table 272. Secondary Sources Table 273. Primary Sources List of Figures Figure 1. Anti-Parkinson's Disease Drugs Image Figure 2. Global Anti-Parkinson's Disease Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Parkinson's Disease Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Anti-Parkinson's Disease Drugs Sales (2021-2032) & (K Units) Figure 5. Anticholinergics Image Figure 6. Global Anticholinergics Sales YoY Growth (2021-2032) & (K Units) Figure 7. Dopaminergics Image Figure 8. Global Dopaminergics Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Anti-Parkinson's Disease Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Anti-Parkinson's Disease Drugs Market Share by Type 2025 VS 2032 Figure 11. North America Anti-Parkinson's Disease Drugs Sales Market Share in Volume by Type in 2025 Figure 12. North America Anti-Parkinson's Disease Drugs Sales Market Share in Value by Type in 2025 Figure 13. Europe Anti-Parkinson's Disease Drugs Sales Market Share in Volume by Type in 2025 Figure 14. Europe Anti-Parkinson's Disease Drugs Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Anti-Parkinson's Disease Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Anti-Parkinson's Disease Drugs Sales Market Share in Value by Type in 2025 Figure 17. Latin America Anti-Parkinson's Disease Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Anti-Parkinson's Disease Drugs Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Anti-Parkinson's Disease Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Anti-Parkinson's Disease Drugs Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Anti-Parkinson's Disease Drugs Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Pharmacy Image Figure 24. Global Pharmacy Sales YoY Growth (2021-2032) & (K Units) Figure 25. Hospital Image Figure 26. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 27. Clinic Image Figure 28. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 29. Other Image Figure 30. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 31. Global Anti-Parkinson's Disease Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Anti-Parkinson's Disease Drugs Market Share by Application 2025 VS 2032 Figure 33. North America Anti-Parkinson's Disease Drugs Sales Market Share in Volume by Application in 2025 Figure 34. North America Anti-Parkinson's Disease Drugs Sales Market Share in Value by Application in 2025 Figure 35. Europe Anti-Parkinson's Disease Drugs Sales Market Share in Volume by Application in 2025 Figure 36. Europe Anti-Parkinson's Disease Drugs Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Anti-Parkinson's Disease Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Anti-Parkinson's Disease Drugs Sales Market Share in Value by Application in 2025 Figure 39. Latin America Anti-Parkinson's Disease Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Anti-Parkinson's Disease Drugs Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Anti-Parkinson's Disease Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Anti-Parkinson's Disease Drugs Sales Market Share in Value by Application in 2025 Figure 43. North America Anti-Parkinson's Disease Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. North America Anti-Parkinson's Disease Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Anti-Parkinson's Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Anti-Parkinson's Disease Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Anti-Parkinson's Disease Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Europe Anti-Parkinson's Disease Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Anti-Parkinson's Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Anti-Parkinson's Disease Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Anti-Parkinson's Disease Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Asia-Pacific Anti-Parkinson's Disease Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Anti-Parkinson's Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Anti-Parkinson's Disease Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Anti-Parkinson's Disease Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Latin America Anti-Parkinson's Disease Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Anti-Parkinson's Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Anti-Parkinson's Disease Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Anti-Parkinson's Disease Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Middle East and Africa Anti-Parkinson's Disease Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Anti-Parkinson's Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Anti-Parkinson's Disease Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Anti-Parkinson's Disease Drugs Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Anti-Parkinson's Disease Drugs Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Anticholinergics
  • Dopaminergics
Applications
  • Pharmacy
  • Hospital
  • Clinic
  • Other
Companies covered
  • Zhejiang Huahai Pharmaceutical Co., Ltd.
  • Tianjin Lisheng Pharmaceutical Co., Ltd.
  • Ningbo Dahongying Pharmaceutical Co., Ltd.
  • Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
  • Hunan Zhongnan Pharmaceutical Co., Ltd.
  • Hangzhou Guoguang Pharmaceutical Co., Ltd.
  • Guangzhou Kanghe Pharmaceutical Co., Ltd.
  • Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.
  • Changzhou Kangpu Pharmaceutical Co., Ltd.
  • Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.
  • Beijing Fuyuan Pharmaceutical Co., Ltd.
  • Valeant
  • Teva Pharmaceutical
  • Stada Arzneimittel
  • Roche Holding AG
  • Orion
  • Novartis
  • Merck
  • Lundbeck
  • Kyowa Kirin
  • GSK
  • Endo International plc
  • Desitin Arzneimittel
  • Boehringer Ingelheim
  • Bausch Health
  • Astellas Pharma
  • Apokyn
  • Akorn
  • Abbvie

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anti-Parkinson's Disease Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Anti-Parkinson's Disease Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Anti-Parkinson's Disease Drugs Market by Type
  6. 1.3.1 Anticholinergics
  7. 1.3.2 Dopaminergics
  8. 1.4 Global Anti-Parkinson's Disease Drugs Market Size by Type
  9. 1.4.1 Global Anti-Parkinson's Disease Drugs Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Anti-Parkinson's Disease Drugs Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Anti-Parkinson's Disease Drugs Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Anti-Parkinson's Disease Drugs Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Anti-Parkinson's Disease Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Anti-Parkinson's Disease Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Anti-Parkinson's Disease Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Anti-Parkinson's Disease Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Anti-Parkinson's Disease Drugs Industry Trends
  2. 2.2 Anti-Parkinson's Disease Drugs Industry Drivers
  3. 2.3 Anti-Parkinson's Disease Drugs Industry Opportunities and Challenges
  4. 2.4 Anti-Parkinson's Disease Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Anti-Parkinson's Disease Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Anti-Parkinson's Disease Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Anti-Parkinson's Disease Drugs Price (2021-2026)
  4. 3.4 Global Anti-Parkinson's Disease Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Anti-Parkinson's Disease Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Anti-Parkinson's Disease Drugs Company, Product Type & Application
  7. 3.7 Global Anti-Parkinson's Disease Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Anti-Parkinson's Disease Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Anti-Parkinson's Disease Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Anti-Parkinson's Disease Drugs Tier 1, Tier 2, and Tier 3
4 Anti-Parkinson's Disease Drugs Regional Status and Outlook
  1. 4.1 Global Anti-Parkinson's Disease Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Anti-Parkinson's Disease Drugs Historic Market Size by Region
  3. 4.2.1 Global Anti-Parkinson's Disease Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Anti-Parkinson's Disease Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Anti-Parkinson's Disease Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Anti-Parkinson's Disease Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Anti-Parkinson's Disease Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Anti-Parkinson's Disease Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Anti-Parkinson's Disease Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Anti-Parkinson's Disease Drugs by Application
  1. 5.1 Anti-Parkinson's Disease Drugs Market by Application
  2. 5.1.1 Pharmacy
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.1.4 Other
  6. 5.2 Global Anti-Parkinson's Disease Drugs Market Size by Application
  7. 5.2.1 Global Anti-Parkinson's Disease Drugs Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Anti-Parkinson's Disease Drugs Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Anti-Parkinson's Disease Drugs Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Anti-Parkinson's Disease Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Anti-Parkinson's Disease Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Anti-Parkinson's Disease Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Anti-Parkinson's Disease Drugs Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Anti-Parkinson's Disease Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Zhejiang Huahai Pharmaceutical Co., Ltd.
  2. 6.1.1 Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information
  3. 6.1.2 Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview
  4. 6.1.3 Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  6. 6.1.5 Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments
  7. 6.2 Tianjin Lisheng Pharmaceutical Co., Ltd.
  8. 6.2.1 Tianjin Lisheng Pharmaceutical Co., Ltd. Company Information
  9. 6.2.2 Tianjin Lisheng Pharmaceutical Co., Ltd. Business Overview
  10. 6.2.3 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  12. 6.2.5 Tianjin Lisheng Pharmaceutical Co., Ltd. Recent Developments
  13. 6.3 Ningbo Dahongying Pharmaceutical Co., Ltd.
  14. 6.3.1 Ningbo Dahongying Pharmaceutical Co., Ltd. Company Information
  15. 6.3.2 Ningbo Dahongying Pharmaceutical Co., Ltd. Business Overview
  16. 6.3.3 Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  18. 6.3.5 Ningbo Dahongying Pharmaceutical Co., Ltd. Recent Developments
  19. 6.4 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
  20. 6.4.1 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Company Information
  21. 6.4.2 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Business Overview
  22. 6.4.3 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  24. 6.4.5 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Developments
  25. 6.5 Hunan Zhongnan Pharmaceutical Co., Ltd.
  26. 6.5.1 Hunan Zhongnan Pharmaceutical Co., Ltd. Company Information
  27. 6.5.2 Hunan Zhongnan Pharmaceutical Co., Ltd. Business Overview
  28. 6.5.3 Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  30. 6.5.5 Hunan Zhongnan Pharmaceutical Co., Ltd. Recent Developments
  31. 6.6 Hangzhou Guoguang Pharmaceutical Co., Ltd.
  32. 6.6.1 Hangzhou Guoguang Pharmaceutical Co., Ltd. Company Information
  33. 6.6.2 Hangzhou Guoguang Pharmaceutical Co., Ltd. Business Overview
  34. 6.6.3 Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  36. 6.6.5 Hangzhou Guoguang Pharmaceutical Co., Ltd. Recent Developments
  37. 6.7 Guangzhou Kanghe Pharmaceutical Co., Ltd.
  38. 6.7.1 Guangzhou Kanghe Pharmaceutical Co., Ltd. Company Information
  39. 6.7.2 Guangzhou Kanghe Pharmaceutical Co., Ltd. Business Overview
  40. 6.7.3 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  42. 6.7.5 Guangzhou Kanghe Pharmaceutical Co., Ltd. Recent Developments
  43. 6.8 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.
  44. 6.8.1 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Company Information
  45. 6.8.2 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Business Overview
  46. 6.8.3 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  48. 6.8.5 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Recent Developments
  49. 6.9 Changzhou Kangpu Pharmaceutical Co., Ltd.
  50. 6.9.1 Changzhou Kangpu Pharmaceutical Co., Ltd. Company Information
  51. 6.9.2 Changzhou Kangpu Pharmaceutical Co., Ltd. Business Overview
  52. 6.9.3 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  54. 6.9.5 Changzhou Kangpu Pharmaceutical Co., Ltd. Recent Developments
  55. 6.10 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.
  56. 6.10.1 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Company Information
  57. 6.10.2 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Business Overview
  58. 6.10.3 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  60. 6.10.5 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Recent Developments
  61. 6.11 Beijing Fuyuan Pharmaceutical Co., Ltd.
  62. 6.11.1 Beijing Fuyuan Pharmaceutical Co., Ltd. Company Information
  63. 6.11.2 Beijing Fuyuan Pharmaceutical Co., Ltd. Business Overview
  64. 6.11.3 Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  66. 6.11.5 Beijing Fuyuan Pharmaceutical Co., Ltd. Recent Developments
  67. 6.12 Valeant
  68. 6.12.1 Valeant Company Information
  69. 6.12.2 Valeant Business Overview
  70. 6.12.3 Valeant Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Valeant Anti-Parkinson's Disease Drugs Product Portfolio
  72. 6.12.5 Valeant Recent Developments
  73. 6.13 Teva Pharmaceutical
  74. 6.13.1 Teva Pharmaceutical Company Information
  75. 6.13.2 Teva Pharmaceutical Business Overview
  76. 6.13.3 Teva Pharmaceutical Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Teva Pharmaceutical Anti-Parkinson's Disease Drugs Product Portfolio
  78. 6.13.5 Teva Pharmaceutical Recent Developments
  79. 6.14 Stada Arzneimittel
  80. 6.14.1 Stada Arzneimittel Company Information
  81. 6.14.2 Stada Arzneimittel Business Overview
  82. 6.14.3 Stada Arzneimittel Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Stada Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolio
  84. 6.14.5 Stada Arzneimittel Recent Developments
  85. 6.15 Roche Holding AG
  86. 6.15.1 Roche Holding AG Company Information
  87. 6.15.2 Roche Holding AG Business Overview
  88. 6.15.3 Roche Holding AG Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Roche Holding AG Anti-Parkinson's Disease Drugs Product Portfolio
  90. 6.15.5 Roche Holding AG Recent Developments
  91. 6.16 Orion
  92. 6.16.1 Orion Company Information
  93. 6.16.2 Orion Business Overview
  94. 6.16.3 Orion Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Orion Anti-Parkinson's Disease Drugs Product Portfolio
  96. 6.16.5 Orion Recent Developments
  97. 6.17 Novartis
  98. 6.17.1 Novartis Company Information
  99. 6.17.2 Novartis Business Overview
  100. 6.17.3 Novartis Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Novartis Anti-Parkinson's Disease Drugs Product Portfolio
  102. 6.17.5 Novartis Recent Developments
  103. 6.18 Merck
  104. 6.18.1 Merck Company Information
  105. 6.18.2 Merck Business Overview
  106. 6.18.3 Merck Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Merck Anti-Parkinson's Disease Drugs Product Portfolio
  108. 6.18.5 Merck Recent Developments
  109. 6.19 Lundbeck
  110. 6.19.1 Lundbeck Company Information
  111. 6.19.2 Lundbeck Business Overview
  112. 6.19.3 Lundbeck Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Lundbeck Anti-Parkinson's Disease Drugs Product Portfolio
  114. 6.19.5 Lundbeck Recent Developments
  115. 6.20 Kyowa Kirin
  116. 6.20.1 Kyowa Kirin Company Information
  117. 6.20.2 Kyowa Kirin Business Overview
  118. 6.20.3 Kyowa Kirin Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Kyowa Kirin Anti-Parkinson's Disease Drugs Product Portfolio
  120. 6.20.5 Kyowa Kirin Recent Developments
  121. 6.21 GSK
  122. 6.21.1 GSK Company Information
  123. 6.21.2 GSK Business Overview
  124. 6.21.3 GSK Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 GSK Anti-Parkinson's Disease Drugs Product Portfolio
  126. 6.21.5 GSK Recent Developments
  127. 6.22 Endo International plc
  128. 6.22.1 Endo International plc Company Information
  129. 6.22.2 Endo International plc Business Overview
  130. 6.22.3 Endo International plc Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 Endo International plc Anti-Parkinson's Disease Drugs Product Portfolio
  132. 6.22.5 Endo International plc Recent Developments
  133. 6.23 Desitin Arzneimittel
  134. 6.23.1 Desitin Arzneimittel Company Information
  135. 6.23.2 Desitin Arzneimittel Business Overview
  136. 6.23.3 Desitin Arzneimittel Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  137. 6.23.4 Desitin Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolio
  138. 6.23.5 Desitin Arzneimittel Recent Developments
  139. 6.24 Boehringer Ingelheim
  140. 6.24.1 Boehringer Ingelheim Company Information
  141. 6.24.2 Boehringer Ingelheim Business Overview
  142. 6.24.3 Boehringer Ingelheim Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  143. 6.24.4 Boehringer Ingelheim Anti-Parkinson's Disease Drugs Product Portfolio
  144. 6.24.5 Boehringer Ingelheim Recent Developments
  145. 6.25 Bausch Health
  146. 6.25.1 Bausch Health Company Information
  147. 6.25.2 Bausch Health Business Overview
  148. 6.25.3 Bausch Health Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  149. 6.25.4 Bausch Health Anti-Parkinson's Disease Drugs Product Portfolio
  150. 6.25.5 Bausch Health Recent Developments
  151. 6.26 Astellas Pharma
  152. 6.26.1 Astellas Pharma Company Information
  153. 6.26.2 Astellas Pharma Business Overview
  154. 6.26.3 Astellas Pharma Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  155. 6.26.4 Astellas Pharma Anti-Parkinson's Disease Drugs Product Portfolio
  156. 6.26.5 Astellas Pharma Recent Developments
  157. 6.27 Apokyn
  158. 6.27.1 Apokyn Company Information
  159. 6.27.2 Apokyn Business Overview
  160. 6.27.3 Apokyn Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  161. 6.27.4 Apokyn Anti-Parkinson's Disease Drugs Product Portfolio
  162. 6.27.5 Apokyn Recent Developments
  163. 6.28 Akorn
  164. 6.28.1 Akorn Company Information
  165. 6.28.2 Akorn Business Overview
  166. 6.28.3 Akorn Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  167. 6.28.4 Akorn Anti-Parkinson's Disease Drugs Product Portfolio
  168. 6.28.5 Akorn Recent Developments
  169. 6.29 Abbvie
  170. 6.29.1 Abbvie Company Information
  171. 6.29.2 Abbvie Business Overview
  172. 6.29.3 Abbvie Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  173. 6.29.4 Abbvie Anti-Parkinson's Disease Drugs Product Portfolio
  174. 6.29.5 Abbvie Recent Developments
7 North America by Country
  1. 7.1 North America Anti-Parkinson's Disease Drugs Sales by Country
  2. 7.1.1 North America Anti-Parkinson's Disease Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Anti-Parkinson's Disease Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Anti-Parkinson's Disease Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Anti-Parkinson's Disease Drugs Market Size by Country
  6. 7.2.1 North America Anti-Parkinson's Disease Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Anti-Parkinson's Disease Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Anti-Parkinson's Disease Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Anti-Parkinson's Disease Drugs Sales by Country
  2. 8.1.1 Europe Anti-Parkinson's Disease Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Anti-Parkinson's Disease Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Anti-Parkinson's Disease Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Anti-Parkinson's Disease Drugs Market Size by Country
  6. 8.2.1 Europe Anti-Parkinson's Disease Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Anti-Parkinson's Disease Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Anti-Parkinson's Disease Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Anti-Parkinson's Disease Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Anti-Parkinson's Disease Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Anti-Parkinson's Disease Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Anti-Parkinson's Disease Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Anti-Parkinson's Disease Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Anti-Parkinson's Disease Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Anti-Parkinson's Disease Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Anti-Parkinson's Disease Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Anti-Parkinson's Disease Drugs Sales by Country
  2. 10.1.1 South America Anti-Parkinson's Disease Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Anti-Parkinson's Disease Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Anti-Parkinson's Disease Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Anti-Parkinson's Disease Drugs Market Size by Country
  6. 10.2.1 South America Anti-Parkinson's Disease Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Anti-Parkinson's Disease Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Anti-Parkinson's Disease Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Anti-Parkinson's Disease Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Anti-Parkinson's Disease Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Anti-Parkinson's Disease Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Anti-Parkinson's Disease Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Anti-Parkinson's Disease Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Anti-Parkinson's Disease Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Anti-Parkinson's Disease Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Anti-Parkinson's Disease Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Anti-Parkinson's Disease Drugs Value Chain Analysis
  2. 12.1.1 Anti-Parkinson's Disease Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Anti-Parkinson's Disease Drugs Production Mode & Process
  7. 12.2 Anti-Parkinson's Disease Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Anti-Parkinson's Disease Drugs Distributors
  10. 12.2.3 Anti-Parkinson's Disease Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst